Cargando…

Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib

Adverse events are anticipated during a clinical development program. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We describe here the process undertaken by Pfizer to investigate a safety signal for pancreatic cancer with tofacitinib. Potential cases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dasic, Gorana, Jones, Thomas, Frajzyngier, Vera, Rojo, Ricardo, Madsen, Ann, Valdez, Hernan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817838/ https://www.ncbi.nlm.nih.gov/pubmed/29417755 http://dx.doi.org/10.1002/prp2.371

Ejemplares similares

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Improving Patient Safety in Hospitals through Usage of Cloud Supported Video Surveillance
por: Dašić, Predrag, et al.
Publicado: (2017)

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
por: Lichtenstein, Gary R, et al.
Publicado: (2022)

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Development of a sensitive biochemical assay for the detection of tofacitinib adherence
por: Church, Stephanie, et al.
Publicado: (2023)

Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Safety of adult medical male circumcision performed by non-physician clinicians in Kenya: a prospective cohort study
por: Frajzyngier, Vera, et al.
Publicado: (2014)

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
por: Winthrop, Kevin L., et al.
Publicado: (2017)

Tofacitinib
Publicado: (2012)

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
por: Lomonte, Andrea B.V., et al.
Publicado: (2018)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis
por: Jones, Nicholas T, et al.
Publicado: (2023)

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2015)

The Role of Tofacitinib in the Management of Alopecia Totalis
por: Hernandez-Montoya, Carlos, et al.
Publicado: (2019)

Erratum to Tofacitinib
Publicado: (2012)

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
por: Clowse, Megan E. B., et al.
Publicado: (2016)

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2018)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
por: Burmester, Gerd R., et al.
Publicado: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
por: Winthrop, Kevin L., et al.
Publicado: (2022)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021)

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
por: Miyoshi, So, et al.
Publicado: (2019)

Tofacitinib is not a biologic
por: Marren, Amy S.
Publicado: (2017)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
por: Charles‐Schoeman, Christina, et al.
Publicado: (2019)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Comments on the article “Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study”
por: Thai, Thuy Nhu, et al.
Publicado: (2018)

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience
por: BİLGİN, Emre, et al.
Publicado: (2021)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3vjeiqumo0d8fm0me2610kn7v2